An observational study in Aortic Valve Stenosis, sponsored by Sahajanand Medical Technologies Limited. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Sahajanand Medical Technologies Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 32nd largest by planned enrollment of the 33 observational ones that give a count, is one of 7 that started in 2024, is one of 33 observational ones, reaches primary completion later than 20 of the 27 other live ones, and was the 64th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark, Sweden
Ages 18+
Anteris Technologies Ltd. · Sites in Denmark
Ages 18+
Ole De Backer · Sites in Denmark, Belgium, Finland and 3 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Novartis Pharmaceuticals · Sites in Denmark, United States, Austria and 12 more countries
Ages 50–80
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 40 interventional studies, 200 across the 33 observational. Of the 37 that completed or were terminated, 10 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 73 have an industry lead sponsor. The 10 most frequent:
Sahajanand Medical Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Sahajanand Medical Technologies Limited has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Aortic Valve Stenosis with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05758662St. Antonius HospitalThe Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) | 2027-06 |
| NCT06638268Rigshospitalet, DenmarkTranscatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock | 2027-07-01 |
| NCT06470022Christian Juhl TerkelsenComparison of Evolut FX Versus Sapien 3 Ultra Resilia. | 2027-07-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study aims to evaluate the efficacy and safety of TAVI using the Hydra transcatheter aortic valve (THV) series, in patients with severe aortic stenosis up to 1-year after the procedure. Additionally, the study will assess the role of geometry in the development of new conduction abnormalities based on the analysis of post-operative CT scan at 1-month in patients who had undergone transcatheter aortic valve replacement with a self-expanding Hydra THV series.
Patient with severe aortic valve stenosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
Primary safety endpoint
Early safety as defined by VARC-3, as composite of: * Freedom from all-cause mortality; * Freedom from all stroke; * Freedom from VARC 3 type 3-4 bleeding; * Freedom from major vascular, access-related, or cardiac structural complication; * Freedom from acute kidney injury stage 3 or 4; * Freedom from moderate or severe aortic regurgitation; * Freedom from new permanent pacemaker due to procedure-related conduction abnormalities; * Freedom from surgery or intervention related to the device.
Time frame: 30 days
Primary performance endpoint
Device success as defined by VARC-3, as composite of: * Technical success; * Freedom from mortality; * Freedom from surgery or intervention related to the device or to a major vascular or access related or cardiac structural complication; * Intended performance of the valve (mean gradient \<20mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation).
Time frame: 30 days
Technical success
Time frame: Immediately after procedure
Cardiovascular mortality
Time frame: 30 days, and 1-year
All-cause mortality
Time frame: 30 days, and 1-year
All stroke
Time frame: 30 days, and 1-year
Disabling stroke
Time frame: 30 days, and 1-year
Myocardial infarction
Time frame: 30 days, and 1-year
Major vascular complication
Time frame: 30 days
Acute kidney injury
Time frame: 30 days
New permanent pacemaker implantation due to procedure related conduction abnormalities
Time frame: 30 days, and 1-year
New-onset atrial fibrillation
Time frame: 30 days, and 1-year
Coronary artery obstruction requiring intervention
Time frame: 30 days, and 1-year
Re-hospitalization for procedure- or valve-related causes
Time frame: 30 days, and 1-year
Mean aortic valve gradient
Time frame: 30 days, and 1-year
Effective Orifice Area (EOA)
Time frame: 30 days, and 1-year
Paravalvular leak
Time frame: 30 days, and 1-year
New York Heart Association (NYHA) functional class
Time frame: 30 days, and 1-year
Quality-of-life evaluation
Time frame: 30 days, and 1-year
Bioprosthetic Valve Failure (BVF)
Time frame: 30 days, and 1-year
Bioprosthetic valve dysfunction (BVD)
Time frame: 30 days, and 1-year
Stroke or peripheral embolism
Time frame: 30 days, and 1-year
VARC-3 Type 3-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents used specifically for valve-related concerns
Time frame: 30 days, and 1-year
Rates of Hypoattenuated Leaflet Thickening (HALT)
Time frame: 30 days
Rates of Reduced leaflet motion (RLM)
Time frame: 30 days
Commissural alignment
Time frame: 30 days
Started Jun 2024 (actual). Primary completion is estimated for Sep 2027, 39 months after the start.
Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 39 months is above that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahajanand Medical Technologies Limited